---
title: "Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib"
description: "Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276393466.md"
published_at: "2026-02-19T23:45:59.000Z"
---

# Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib

### President's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) just unveiled an announcement.

Hansoh Pharmaceutical Group announced that its innovative lung cancer drug Aumolertinib Mesylate Tablets, marketed as Ameile in China and Aumseqa outside China, has received European Union approval as a monotherapy. The authorization covers first-line treatment of adults with advanced EGFR-mutated non-small cell lung cancer, as well as patients with advanced EGFR T790M mutation-positive disease, following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.

The EU approval significantly extends the global reach of Aumolertinib, which already holds multiple indications in China and marketing authorization in the U.K. This milestone strengthens Hansoh’s position in the competitive global oncology market and underscores its transition from a domestic innovator to an international player in targeted cancer therapies, with potential benefits for its growth prospects and international partnerships.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$44.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

**More about Hansoh Pharmaceutical Group Company Limited**

Hansoh Pharmaceutical Group Company Limited is a China-based pharmaceutical company focused on innovative therapies, particularly in oncology. Its portfolio includes Aumolertinib Mesylate Tablets, a third-generation EGFR tyrosine kinase inhibitor used to treat various forms and stages of non-small cell lung cancer, reflecting a strategic emphasis on targeted cancer treatments in both domestic and international markets.

**Average Trading Volume:** 8,280,646

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$223.4B

### Related Stocks

- [03692.HK - HANSOH PHARMA](https://longbridge.com/en/quote/03692.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 翰森制药宣布，甲磺酸奥莫替尼片在欧盟获批用于单药治疗 | 汉森制药集团有限公司：AUMOLERTINIB 美克替尼片在欧盟作为单药治疗获得批准 | [Link](https://longbridge.com/en/news/276401882.md) |
| 翰森制药集团有限公司宣布其单药疗法在欧盟获得批准 | 汉森制药集团有限公司宣布，阿莫雷替尼美克沙片（在中国称为 Ameile）获得欧盟批准，作为单药治疗用于治疗晚期非小细胞肺癌（NSCLC）。这包括针对特定 EGFR 突变的成人患者的首选治疗，以及针对 EGFR T790M 突变阳性 NSCL | [Link](https://longbridge.com/en/news/276480305.md) |
| 翰森制药的旗舰肺癌药物阿美乐获得了中国的第五次批准 | 汉森制药集团在中国获得了其肺癌药物 Ameile 的第五次批准，允许其与化疗联合使用，适用于具有特定 EGFR 突变的成人。这一批准增强了 Ameile 的临床应用，并巩固了汉森在肿瘤市场的地位。该股票被评级为买入，目标价为 48.20 港 | [Link](https://longbridge.com/en/news/271915761.md) |
| 斥资 185 亿美元牵手石药集团后，阿斯利康每股收益预增双位数 | 阿斯利康预计 2026 年每股收益将实现两位数增长，肿瘤药物销售强劲有望抵消糖尿病药物专利到期影响。公司近期以高达 185 亿美元引入石药集团长效肽技术，加速布局 GLP-1 减肥药市场。尽管面临美国药价政策调整，公司通过协议获得关税豁免。 | [Link](https://longbridge.com/en/news/275425282.md) |
| 翰森制药将通过发行零息可转换债券筹集 46.8 亿港元 | 汉森制药集团有限公司计划通过发行 2033 年到期的零息可转换债券筹集 46.8 亿港元。这些债券可转换为约 8150 万股，初始价格为每股 57.39 港元，将向香港的专业投资者及美国以外的投资者发售。净收益将按照公司指定的用途使用，但完 | [Link](https://longbridge.com/en/news/273753448.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.